INTRODUCTION
The results of cancer genome resequencing show that most genes with driver alterations (i.e., cancer genes) are tumor and even sample specific (Ciccarelli, 2010; Vogelstein et al., 2013) . Such high genetic heterogeneity explains why very few drugs are effective for a large spectrum of cancers, whereas the most powerful therapies are tailored to the genetics of the individual tumors (Black and Morris, 2012) . Cancer genes have thus been thoroughly studied to identify targets of anticancer therapy. For example, large efforts have been devoted to identify synthetic lethal interactions between known cancer genes such as KRAS (Barbie et al., 2009) , EGFR (Dong et al., 2010) , BRCA1, and BRCA2 (Bryant et al., 2005; Farmer et al., 2005) . In this latter case, clinical trials have been designed to treat BRCA-mutated cancers with inhibitors of PARP1, which has a negative interaction with BRCA genes (Ashworth, 2008 ).
Here, we tested the hypothesis that paralogs of cancer genes, i.e., genes that originated via gene duplication, might act as negative interactors due to functional redundancy between multiple gene copies. Negative genetic interactions between paralogs exist in yeast where the deletion of duplicated genes significantly reduces cell fitness, whereas the deletion of only one paralog leads to no phenotypic change (VanderSluis et al., 2010) . If similar negative interactions occur in human, paralogs of cancer-promoting genes could be used as specific targets to block tumor growth. To test this hypothesis, we identified a list of putative cancer gene interactors and experimentally blocked the functional paralogs of three of them (SMARCA4, CDH1, and DNMT3A), as a proof of principle. In the case of SMARCA4 and CDH1, paralog silencing significantly reduced cell proliferation only in cancer cell lines where the cancer gene was mutated. In the case of DNMT3A, only the concomitant silencing of all functionally redundant genes-two of which were paralogs and one shared a functional domain-led to significant decrease in cell proliferation.
RESULTS

Identification of Paralogs of Recessive Cancer Genes
Dominant and recessive cancer genes roughly correspond to oncogenes and tumor suppressors, respectively, because oncogenes usually, but not always, require heterozygousactivating mutations to exert their role in the disease. Tumor suppressors, instead, need inactivation of both alleles to totally impair their anticancer function (Vogelstein and Kinzler, 2004) . Given this difference, negative genetic interactions due to functional compensation should preferentially involve duplicated recessive cancer genes because the loss of function can be at least partially rescued by the paralog (Figure 1) . As a consequence, silencing the paralog of a duplicated recessive gene should selectively affect the cancer cells that bear the inactivated gene but not the normal counterpart (Figure 1 ).
To test this hypothesis, we identified the paralogs of 99 recessive cancer genes (Futreal et al., 2004) , defined as additional gene copies covering at least 20% of the protein length (see Experimental Procedures). Of 99 genes, 23 were duplicated (23.2% of the total, Table S1 ). This was a significantly lower fraction compared to other human genes (38.5%; p = 0.002, Fisher's exact test) and confirmed the tendency of cancer genes, and in particular of recessive genes, to retain only one gene copy (D'Antonio and Ciccarelli, 2011; Rambaldi et al., 2008) . Interestingly, in more than 65% of cases, we found support from the literature for functional compensation between recessive genes and their paralogs (Table S1) .
To further validate our hypothesis, we experimentally tested the predicted negative genetic interactions among three recessive genes (SMARCA4, CDH1, and DNMT3A) and their corresponding paralogs (SMARCA2, CDH3, and DNMT3B). These genes were selected because they had (1) only one paralog, thus avoiding having to experimentally silence multiple gene copies, (2) published evidence of functional redundancy with their paralogs, and (3) cancer cell lines with homozygous nonsilent mutations available for screening (Table S1 ). Although these three cases constituted the best candidates to test our hypothesis, we also predict negative genetic interactions between the other recessive genes and their paralogs. For all three genes, we compared the effect of silencing the corresponding paralog on the proliferation of the mutated cancer cell line and of the wild-type control.
SMARCA2 and CDH3 Engage Negative Genetic Interactions with the Tumor Suppressors SMARCA4 and CDH1 SMARCA4 and SMARCA2 encode two mutually exclusive DNAdependent ATPases of the SWI/SNF complex (Reisman et al., 2009) . SMARCA4-and SMARCA2-containing complexes are functionally redundant in adult tissues, where one paralog is able to compensate for the loss of the other (Willis et al., 2012) . SMARCA4 is a known tumor suppressor in several primary tumors (Rodriguez-Nieto et al., 2011) and particularly in nonsmall-cell lung cancers (Reisman et al., 2003) . SMARCA2 knockout mice, instead, do not show any increased predisposition to cancer (Bultman et al., 2008) .
We silenced SMARCA2 in two glioblastoma cell lines: one with a SMARCA4 homozygous-truncating mutation that removes the protein bromodomain (GAMG), and the other with the wild-type gene (LN405, Figure 2A ). Upon silencing via transient RNAi, SMARCA2 expression decreased in both cell lines ( Figure 2B ). However, whereas SMARCA2 silencing significantly reduced cell proliferation in SMARCA4 mutated cells, it had no appreciable effects on the proliferation of SMARCA4 wild-type cells ( Figure 2C ). To verify the long-term effect of SMARCA2 silencing, we blocked its expression in GAMG and LN405 cell lines using a lentiviral vector that stably expressed an anti-SMARCA2 shRNA ( Figure 2D ). The colony assay showed severe proliferation reduction in GAMG cells, whereas no difference was detected in LN405 cells ( Figures 2E and S1 ). As a further confirmation, we silenced SMARCA4 and SMARCA2 simultaneously in LN405 cells ( Figure 2F ) and observed that cells that did not express either paralog had significantly decreased proliferation rate as compared to wild-type cells. Cells with only one blocked gene did not show any difference ( Figure 2G ). Altogether, our results sustain the presence of a negative genetic interaction between SMARCA4 and SMARCA2 that is not cell line dependent.
As a second case study, we tested the negative genetic interaction between CDH1 and CDH3, which encode members of the type 1 cadherin family (Hulpiau and van Roy, 2009; Saito et al., 2012) . The two paralogous genes have the same structure and function, although CDH1 is tissue specific, whereas CDH3 is widely expressed (Saito et al., 2012) . Although there is no evidence of CDH3 involvement in cancer, CDH1 is a driver of epithelial tumors (Mastracci et al., 2005; Shah et al., 2012) . We first confirmed the presence of the CDH1 homozygous nonsense mutation in the breast cancer cell line ZR75-30, which results in the loss of more than 70% of the protein, and its absence in the control cells (ZR75-1, Figure 3A ). We then inhibited CDH3 expression via transient RNAi in both cell lines ( Figure 3B ) and observed significant decrease in cell proliferation only in the cell line with the mutated CDH1 ( Figure 3C ).
In summary, our experiments confirmed the predicted negative genetic interactions between both pairs of recessive genes and their functional paralogs. In both cases, silencing the cancer gene paralog reduced cell proliferation only when the recessive gene was also mutated. Figure S1 . (F) Expression levels of SMARCA4 and SMARCA2 in LN405 cells upon silencing of only SMARCA4, only SMARCA2, and of both genes as compared to scrambled. (G) Proliferation assay of cells treated with only anti-SMARCA4 siRNA, only anti-SMARCA2 siRNA, and both siRNAs. Two biological replicates were made for each experiment, except for the double KD where three replicates were made. Mean and SE refer to the counts of BrdUpositive cells across several images of one replicate. Student's t test was performed between scrambled and silenced cells. See also Figure S1 and Table S2 .
Trigenic Negative Interaction Occurs among the Tumor Suppressor DNMT3A, Its Paralog DNMT3B, and the Residual Functional Compensator DNMT1 DNMT3A and DNMT3B are functionally redundant genes (Pawlak and Jaenisch, 2011 ) that encode two de novo methyltransferases responsible for the establishment of the methylation pattern during embryonic development (Jones and Liang, 2009 ). In adult tissues, DNMT3A and DNMT3B methylate newly replicated CpG sites and repetitive elements (Jones and Liang, 2009) . Inactivating mutations in DNMT3A are found in 25% of acute myeloid leukemia, where they correlate with poor survival (Ley et al., 2010) . To date, no evidence links DNMT3B mutations to cancer.
In OCI-AML2 leukemia cells, the homozygous mutation of DNMT3A leads to amino acid substitution in the DNA-methylase domain ( Figure 4A ). We stably silenced the expression of the cancer gene paralog (DNMT3B) in the mutated cell line and in the wild-type control (AML193, Figure S2A ). However, unlike for SMARCA4 and CDH1, in this case, we detected no effects on cell proliferation in either cell line ( Figures S2B and S2C ), thus suggesting that no direct negative genetic interactions occur between DNMT3A and DNMT3B. One possible reason could be that the missense mutation in DNMT3A is able to drive tumorigenesis (Renneville et al., 2012) but not to abolish the gene function. Therefore, no functional compensation is required. An alternative and intriguing explanation could be the presence of a third gene that may further compensate for the lack of function upon impairment of DNMT3A and DNMT3B. This scenario was suggested by the observation that only one other human gene (DNMT1) encodes a DNA-methylase domain. DNMT1 does not share any sequence conservation with DNMT3A and DNMT3B, and the encoded protein has a different domain composition ( Figure 4B ). As a consequence, DNMT1 is not a gene that evolved via gene duplication of DNMT3A and DNMT3B. Despite the overall lack of sequence conservation, also DNMT1 encodes a divergent DNA-methylase domain that nevertheless may replace the methylase activity in case of impairment of DNMT3A and DNMT3B. As a first indication that this may indeed be the case, we detected DNMT1 overexpression when both genes were silenced as compared to the expression levels when only DNMT3B was blocked ( Figure 4C ). To verify the effect of the silencing of all three genes, we stably silenced DNMT1 in the OCI-AML2 cell line already treated with anti-DNMT3B shRNA ( Figure 4D ), therefore establishing cancer cells without functional DNA methylases. This led to decreased cell proliferation (Figure 4E) as detected by FACS analysis. As a comparison, we stably silenced DNMT1 alone in the AML193 ( Figure 4F ). Although also in this case we observed a decreased cell proliferation, the comparison of the relative decrease of bromodeoxyuridine (BrdU)-positive cells in the two cell lines showed that the cumulative effect of blocking the three genes was significantly higher than blocking only DNMT1 ( Figure 4G ). The synergistic DNMT function is therefore essential for cell viability, and a trigenic negative interaction exists among the three genes.
DISCUSSION
In this paper, we investigated negative genetic interactions that may occur between cancer genes and their paralogs. We focused in particular on duplicated recessive genes because they are mostly affected by loss-of function mutations, and thus, they are predisposed to negative genetic interactions due to functional redundancy (VanderSluis et al., 2010) . However, this does not exclude negative genetic interactions between dominant cancer genes and their paralogs because even gainof-function mutations may lead to modification of the original gene function. Thus, paralogs of dominant cancer genes might act as functional compensators. Similarly, single-copy cancer genes may also engage in negative genetic interactions with nonparalogous genes. For example, compensatory synthetic lethality has been described between the dominant and singleton cancer gene EGFR and members of the NOTCH pathway (Dong et al., 2010) . Therefore, this study tested the hypothesis of genetic interactions between functionally redundant paralogs but does not exclude other causes of synthetic lethality. Table S2 .
Using a variety of assays and different genetic backgrounds, we confirmed digenic negative genetic interactions in two tested gene pairs (SMARCA4 and CDH1) that act as tumor suppressors in a large spectrum of epithelial tumors (Forbes et al., 2011) . Inhibition of their paralogs could therefore arrest or at least reduce tumor growth in several cancer types. Furthermore, both SMARCA2 and CDH3 have been already exploited as drug targets. For example, SMARCA4 and SMARCA2 knockdown cells are hypersensitive to cisplatin (Kothandapani et al., 2012) , a chemotherapeutic drug that increases the DNA damage levels by crosslinking DNA (Pruefer et al., 2008) . Similarly, CDH3 is the target of the monoclonal antibody PF-03732010 in both cell-based assays and tumor models (Zhang et al., 2010) , and phase 1 clinical trials on human patients with cancer are currently ongoing. Although these preliminary data are encouraging, additional experiments are needed to assess (G) Relative decrease of BrdU-positive cells after normalization for the basal proliferation rate of AML193 and OCI-AML2, respectively. Statistical significance was assessed using chi-square test. All experiments were made in duplicate; the results of only one replicate are shown. See also Figure S2 and Table S2. the real efficacy of gene blocking. For example, in cell lines, we observed a statistically significant reduction but never a complete abolishment of cell proliferation. Direct quantification of tumor growth upon paralogous gene blocking in lesions with mutations in SMARCA4 or CDH1 is therefore required. Another factor to consider is the possible multiplicative effect due to functional redundancy among several genes. A good example of this is the trigenic interaction that we detected among DNMT3A, DNMT3B, and DNMT1. The latter has no paralogy relationships with either DNMT3A or DNMT3B but was nevertheless able to rescue the function due to the methylase domain. In this case, all three genes, and not only the two paralogs, must be blocked in order to observe a major effect on cell proliferation. Although case by case validation is required in order to assess whether single genes can be used as therapeutic targets, our study provides a proof of principle that negative genetic interactions exist between cancer genes and their paralogs.
EXPERIMENTAL PROCEDURES Identification of Duplicated Recessive Cancer Genes
A list of 103 recessive cancer genes was retrieved from the Cancer Gene Census (frozen on November 15, 2011) (Futreal et al., 2004) . Four genes (CBL, IKZF1, CREBBP, and PRKAR1A) were discarded because they were defined both as dominant and recessive, thus leading to a total of 99 recessive cancer genes.
To identify duplicated recessive cancer genes, a modified version of our previously developed method (Rambaldi et al., 2008) was applied. In brief, protein sequences from RefSeq v.51 (Pruitt et al., 2009 ) were aligned to the human reference genome (hg19) with BLAT (Kent, 2002) , with parameters Àt = dnax, Àq = prot, minimal score = 0, and minimal identity = 0. The direct alignment of human proteins to the human genome avoided problems of multiple gene isoforms, missing paralogs, and low sensitivity. A ''hit'' was defined as the portion of the human genome that aligned to the original protein sequence. The hit with the highest coverage (i.e., fraction of aligned protein sequence) was defined as the original gene locus. All additional hits covering at least 20% of the original protein length and mapping on a transcribed locus were considered as duplications. Out of the 33,398 initial proteins, 19,045 entries corresponded to unique human genes (i.e., genes mapping to distinct and nonoverlapping genomic loci). The remaining 14,353 sequences were isoforms (12,915 entries), mapped on noncanonical or mitochondrial chromosomes (1,404 entries), or did not align to the human genome (34 entries). Of 19,045 genes, 7,323 had at least one paralog, and 23 were duplicated recessive genes.
Selection of Gene Pairs for Experimental Validation
Information about mutations in cancer cell lines was downloaded from COSMIC v.57 (frozen on January 18, 2012) (Forbes et al., 2011) and from the Cell Line Project v.67 (http://www.sanger.ac.uk/genetics/CGP/CellLines/). Mutation data integration from the two sources pinpointed 665 cell lines with homozygous mutations in 36 recessive genes, 10 of which were duplicated. Of those, three genes (SMARCA4, CDH1, and DNMT3A) were used for experimental validation because they had only one paralog and literature support of functional redundancy (Table S1 ). Protein domains in these genes were annotated using SMART (Letunic et al., 2012) .
DNA was extracted from each of the six cell lines (GAMG, LN405, ZR75-30, ZR75-1, OCI-AML2, and AML193) using DNeasy Blood & Tissue Kit (Qiagen), following the manufacturer's procedures. PCR amplification and Sanger sequencing were performed to confirm the homozygous mutations reported in the literature (Table S2) .
Quantitative RT-PCR
In each cell line, total RNA was collected using TRIzol (Life Technologies), according to the manufacturer's protocol, quantified, and quality controlled.
Reverse transcription was performed on 500 ng RNA with SuperScript VILO cDNA Synthesis Kit (Life Technologies). Changes in gene expression were detected using Applied Biosystems Fast SYBR Green Master Mix. Each real-time PCR assay was performed in triplicate using an Applied Biosystems 7500 Fast Real-Time PCR System Thermal Cycler. The fold enrichment was calculated as log 2 of the mean fold over the control, using b-actin as housekeeping gene (Table S2) .
Transient RNAi, BrdU Assay, and Immunofluorescence Two independent RNAi oligos specific for SMARCA2 and CDH3 were retrieved from Stealth Select RNAi small interfering RNA (siRNA; Life Technologies). An unrelated oligo was used as control (Table S2) . Transfection was performed with QIAGEN-HiPerFect Transfection Reagent, according to the manufacturer's protocol. All RNAi oligos were used at a final concentration of 50 nM. Each transfection mix was incubated with cells for 16 hr at 37 C and then replaced with fresh medium. Cells were plated ($100,000/well in a 6-well plate) on gelatin-coated coverslips to reach a final concentration of 0.5% w/v. BrdU assay was performed 48 hr after transfection. BrdU was directly added to the medium at a final concentration of 10 mM and incubated with cells for different time periods, according to their proliferation rate (1 hr for LN405/GAMG, 6 hr for ZR75-30/ZR75-1). Cells were then fixed for 10 min at room temperature with paraformaldehyde 4% w/v (in PIPES buffer) and permeabilized with Triton X-100 0.1% for 10 min at room temperature. The primary antibody mix was prepared in PBS-BSA 3% w/v, according to the following recipe: mouse anti-BrdU antibody (1:40 v/v), Promega DNase (1:10 v/v), Promega DNase Buffer (1:10 v/v), and MgCl 2 (final concentration, 5 mM) and incubated for 45 min at room temperature in a humid chamber. The secondary antibody mix (anti-mouse Cy3, 1:400 v/v in PBS-BSA 3% w/v) was incubated for an additional 45 min at room temperature, light protected. After DAPI staining, the coverslips were mounted with Moviol medium and observed by optical fluorescence microscope. A total of 5-15 images from each cell culture were acquired, and the fraction of BrdU-positive cells was counted independently for each image. Student's t test was performed between scrambled and KD cells. Two biological replicates were made for each experiment, except for the double KD of SMARCA2 and SMARCA4, where three replicates were made.
Stable RNAi and Colony Assay
In case of SMARCA2, DNMT3B, and DNMT1, gene expression was blocked with stable RNAi using pSICOR vectors (from the Jackson Laboratory, http://web.mit.edu/jacks-lab/protocols/pSico.html) to clone specific shRNA oligos in the target cell lines. Two different 5 0 phosphorylated, PAGE-purified oligos were designed for this gene using the program PSICOLIGOMAKER 1.5 (Reynolds et al., 2004) (Table S2 ). Oligo cloning was performed according to the protocol from The Jacks Lab (http://web.mit.edu/jacks-lab/protocols/ pSico.html). Briefly, oligos were diluted in 23 annealing buffer (200 mM potassium acetate, 60 nM HEPES-KOH [pH 7.4], 4 mM Mg-acetate), annealed for 4 min at 95 C, followed by 10 min at 70 C, and slowly cooled down to 4 C.
Then pSICOR vector was digested with HpaI and XhoI (New England Biolabs) and ligated with the oligo pairs for 3 hr at room temperature. A total of 2 ml of each ligation was transformed using One Shot TOP10 Chemically Competent Escherichia coli (Life Technologies), and positive clones were checked by XhoI-XbaI digestion. Positive clones were selected for the presence of 400 bp fragment (compared with 350 bp of the empty vectors) and sequenced using Sanger sequencing for confirmation (Table S2) . 293T amphotropic cells were transfected using Calcium Phosphate with a DNA mix containing viralpackaging constructs and pSICOR-sh constructs for each of the three genes. Each time, a pSICOR-empty vector was used as a control. At 48 hr after transfection, viral supernatant was collected and used to infect target cells (GAMG and LN405 for SMARCA2; OCI-AML2 and AML193 for DNMT3B and DNMT1). Stably infected cells were selected using 1 mg/ml puromycin for GAMG, LN405 and 4 mg/ml for OCI-AML2, AML193 48 hr after the infection. Two biological replicates were made for each experiment. Stably transfected GAMG and LN405 cells were plated in 10 cm plates at low density (1,000, 5,000, or 10,000 cells) in complete medium with puromycin and grown at 37 C for 14 days. Colonies were stained with crystal violet solution (1% w/v in ethanol 35%) and fixed at room temperature.
FACS Analysis
To assess the effect of sh-DNMT3B and sh-DNMT1 on cell proliferation of the two suspension cell lines (OCI-AML2 and AML193), cells were plated in T-25 flasks at the typical density (http://www.lgcstandards-atcc.org). BrdU assay was performed 16 hr after plating and incubated with cells for 3 hr. Cells were then fixed with cold 70% ethanol, dropwise while vortexing (1 ml/million), washed in PBS-BSA 1% w/v, and permeabilized with denaturing solution (2N HCl) for 25 min at room temperature. After neutralization with 3 vol sodium borate 0.1 M (pH 8.5) for 5 min at room temperature, cells were washed with PBS-BSA 1% w/v and incubated in primary antibody mix for 1 hr at room temperature, light protected. The primary antibody mix (mouse anti-BrdU antibody, 1:5 v/v) was prepared in PBS-BSA 1% w/v. The secondary antibody mix (anti-mouse FITC, 1:50 v/v in PBS-BSA 1% w/v) was incubated for an additional hour at room temperature, light protected. Finally, cells were incubated with propidium iodide (PI) solution (final concentration of 2.5 mg/ml, in PBS) plus RNase (1:40 v/v) overnight at 4 C. After incubation, they were analyzed by FACS for PI content, and the fraction of BrdU-positive cells over the total was calculated. Two biological replicates were made for each experiment.
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